| Title: | Molecular basis for mid-region amyloid-beta capture by leading Alzheimer's disease immunotherapies |
| Authors: | Crespi, GAN Hermans, SJ Parker, MW Miles, LA |
| Issue Year: | 2015 |
| Publisher | NATURE PUBLISHING GROUP |
| Series | Scientific Reports: 5(): - |
| Abstract | Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-beta (A beta) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals. A beta capture by these clinical antibodies is explained here with the first reported mid-region A beta-anti-A beta complex crystal structure. Solanezumab accommodates a large A beta epitope (960 angstrom(2) buried interface over residues 16 to 26) that forms extensive contacts and hydrogen bonds to the antibody, largely via main-chain A beta atoms and a deeply buried Phe19-Phe20 dipeptide core. The conformation of A beta captured is an intermediate between observed sheet and helical forms with intramolecular hydrogen bonds stabilising residues 20-26 in a helical conformation. Remarkably, A beta-binding residues are almost perfectly conserved in crenezumab. The structure explains the observed shared cross reactivity of solanezumab and crenezumab with proteins abundant in plasma that exhibit this Phe-Phe dipeptide. |
| URI: | https://publications.svi.edu.au/publications/1820 |
| Other Identifiers | 10.1038/srep09649 |
| Publication type | Article |
| Grant ID | GNT1021645; GNT1021935 |
| Find it online | http://www.nature.com/srep/2015/150409/srep09649/pdf/srep09649.pdf |